Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$3.52 USD
+0.24 (7.32%)
Updated May 3, 2024 04:00 PM ET
After-Market: $3.51 -0.01 (-0.28%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Brokerage Reports
Aquestive Therapeutics, Inc. [AQST]
Reports for Purchase
Showing records 161 - 180 ( 397 total )
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant New Drug Application Resubmitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Libervant NDA Resubmitted On Schedule, PDUFA Expected in Late 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Solid Quarter With Top- and Bottom-Line Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Aquestive Therapeutics, Inc.
Industry: Medical - Drugs
Q1 Financials; On-track to Resubmit Libervant™ NDA in June
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L